FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

The Ministry of Public Health (MOPH) has recently organised a training workshop for around 90 health service providers from ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

New research from the University of Vermont reveals exposure to smoke from Canadian wildfires in the summer of 2023 led to ...

Personal narratives on allergy and asthma conditions which contained inaccuracies gained the most traction online.

A shock survey by charity Asthma + Lung UK reveals that more than 90% of people with COPD are receiving inadequate care ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...